載入...
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
Abnormal activation of hedgehog pathway signaling is a key driver in the pathogenesis of basal cell carcinoma (BCC). Vismodegib, a first-in-class small-molecule inhibitor of hedgehog pathway signaling, is approved by regulatory authorities for the treatment of adults who have metastatic BCC or local...
Na minha lista:
發表在: | Oncologist |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
AlphaMed Press
2016
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5061532/ https://ncbi.nlm.nih.gov/pubmed/27511905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0186 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|